Skip to main content
Top
Gepubliceerd in:

05-09-2017

Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients

Auteurs: Adrienn Katalin Poór, Fanni Rencz, Valentin Brodszky, László Gulácsi, Zsuzsanna Beretzky, Bernadett Hidvégi, Péter Holló, Sarolta Kárpáti, Márta Péntek

Gepubliceerd in: Quality of Life Research | Uitgave 12/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

The purpose of this study is to assess the measurement properties of EQ-5D-5L compared to EQ-5D-3L in psoriasis patients.

Methods

A cross-sectional survey was carried out at an academic dermatology clinic in Hungary. Psoriasis patients completed the EQ-5D-3L, EQ-5D-5L and Dermatology Life Quality Index (DLQI) questionnaires, and Psoriasis Area and Severity Index (PASI) was assessed. The UK value sets were used to calculate the 3L and 5L index scores. We tested the feasibility, ceiling effect, redistribution properties, the level of inconsistency and informativity (Shannon and Shannon Evenness indices). Spearman’s rank-order correlations were performed between EQ-5D, EQ VAS, DLQI and PASI scores. Known-groups validity was evaluated by comparing age groups, clinical subtypes and treatment groups.

Results

Mean age of the 238 patients was 47 years, and 36.6% of them received biological therapy. Mean EQ-5D index score was 0.77 (SD: 0.26) with the 3L and 0.84 (SD: 0.19) with the 5L. The overall ceiling effect decreased from 37.1 (3L) to 32.9% (5L). Shannon index improved significantly for most dimensions, but Shannon Evenness index improved only in three dimensions. Compared to the 3L, the 5L version confirmed a better convergent validity with PASI, but not with the DLQI. Known-groups validity was equally demonstrated both for the 5L and 3L.

Conclusions

The EQ-5D-5L seems to improve measurement properties by reducing ceiling effects, strengthening correlations with PASI and improving informativity. Follow-up studies are needed to test responsiveness and reliability in psoriasis.
Literatuur
1.
go back to reference Michalek, I. M., Loring, B., & John, S. M. (2017). A systematic review of worldwide epidemiology of psoriasis. Journal of the European Academy of Dermatology and Venereology, 31(2), 205–212.CrossRefPubMed Michalek, I. M., Loring, B., & John, S. M. (2017). A systematic review of worldwide epidemiology of psoriasis. Journal of the European Academy of Dermatology and Venereology, 31(2), 205–212.CrossRefPubMed
3.
go back to reference Ahmed, N., Prior, J. A., Chen, Y., Hayward, R., Mallen, C. D., & Hider, S. L. (2016). Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clinical Rheumatology, 35(12), 3069–3073.CrossRefPubMed Ahmed, N., Prior, J. A., Chen, Y., Hayward, R., Mallen, C. D., & Hider, S. L. (2016). Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clinical Rheumatology, 35(12), 3069–3073.CrossRefPubMed
4.
go back to reference Frieder, J., & Ryan, C. (2016). Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol, 151(6), 678–693.PubMed Frieder, J., & Ryan, C. (2016). Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol, 151(6), 678–693.PubMed
6.
go back to reference van der Voort, E. A., Wakkee, M., Veldt-Kok, P., Darwish Murad, S., & Nijsten, T. (2016). Enhanced liver fibrosis test (ELF) in psoriasis, psoriatic arthritis and rheumatoid arthritis patients: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). British Journal Dermatology, 30, 7. van der Voort, E. A., Wakkee, M., Veldt-Kok, P., Darwish Murad, S., & Nijsten, T. (2016). Enhanced liver fibrosis test (ELF) in psoriasis, psoriatic arthritis and rheumatoid arthritis patients: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). British Journal Dermatology, 30, 7.
7.
go back to reference Mortezavi, M., Thiele, R., & Ritchlin, C. (2015). The joint in psoriatic arthritis. Clinical and Experimental Rheumatology, 33(5 Suppl 93), S20–S25.PubMed Mortezavi, M., Thiele, R., & Ritchlin, C. (2015). The joint in psoriatic arthritis. Clinical and Experimental Rheumatology, 33(5 Suppl 93), S20–S25.PubMed
8.
go back to reference de Korte, J., Sprangers, M. A., Mombers, F. M., & Bos, J. D. (2004). Quality of life in patients with psoriasis: a systematic literature review. Journal of Investigative Dermatology Symposium Proceedings, 9(2), 140–147.CrossRef de Korte, J., Sprangers, M. A., Mombers, F. M., & Bos, J. D. (2004). Quality of life in patients with psoriasis: a systematic literature review. Journal of Investigative Dermatology Symposium Proceedings, 9(2), 140–147.CrossRef
9.
go back to reference Obradors, M., Blanch, C., Comellas, M., Figueras, M., & Lizan, L. (2016). Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Quality of Life Research, 25(11), 2739–2754.CrossRefPubMed Obradors, M., Blanch, C., Comellas, M., Figueras, M., & Lizan, L. (2016). Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Quality of Life Research, 25(11), 2739–2754.CrossRefPubMed
10.
go back to reference Moller, A. H., Erntoft, S., Vinding, G. R., & Jemec, G. B. (2015). A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas, 6, 167–177.PubMedPubMedCentral Moller, A. H., Erntoft, S., Vinding, G. R., & Jemec, G. B. (2015). A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas, 6, 167–177.PubMedPubMedCentral
11.
go back to reference Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., Jr., & Reboussin, D. M. (1999). Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology, 41(3 Pt 1), 401–407.CrossRefPubMed Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., Jr., & Reboussin, D. M. (1999). Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology, 41(3 Pt 1), 401–407.CrossRefPubMed
12.
go back to reference Ellis, C. N., Reiter, K. L., Wheeler, J. R., & Fendrick, A. M. (2002). Economic analysis in dermatology. Journal of the American Academy of Dermatology, 46(2), 271–283.CrossRefPubMed Ellis, C. N., Reiter, K. L., Wheeler, J. R., & Fendrick, A. M. (2002). Economic analysis in dermatology. Journal of the American Academy of Dermatology, 46(2), 271–283.CrossRefPubMed
13.
go back to reference Gutknecht, M., Krensel, M., & Augustin, M. (2016). Health economic analyses of psoriasis management: A systematic literature search. Archives of Dermatological Research, 308(9), 601–616.CrossRefPubMed Gutknecht, M., Krensel, M., & Augustin, M. (2016). Health economic analyses of psoriasis management: A systematic literature search. Archives of Dermatological Research, 308(9), 601–616.CrossRefPubMed
14.
go back to reference Pereira, F. R., Basra, M. K., Finlay, A. Y., & Salek, M. S. (2012). The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology, 225(1), 45–53.CrossRefPubMed Pereira, F. R., Basra, M. K., Finlay, A. Y., & Salek, M. S. (2012). The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology, 225(1), 45–53.CrossRefPubMed
15.
go back to reference EuroQol, G. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef EuroQol, G. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef
17.
go back to reference Devlin, N. J., & Krabbe, P. F. (2013). The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ, 14(Suppl 1), S1–S3.CrossRefPubMed Devlin, N. J., & Krabbe, P. F. (2013). The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ, 14(Suppl 1), S1–S3.CrossRefPubMed
18.
go back to reference Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.CrossRefPubMedPubMedCentral Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.CrossRefPubMedPubMedCentral
19.
go back to reference Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Quality of Life Research, 22(7), 1717–1727.CrossRefPubMed Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Quality of Life Research, 22(7), 1717–1727.CrossRefPubMed
20.
go back to reference Feng, Y., Devlin, N., & Herdman, M. (2015). Assessing the health of the general population in England: How do the three- and five-level versions of EQ-5D compare? Health and Quality of Life Outcomes, 13, 171.CrossRefPubMedPubMedCentral Feng, Y., Devlin, N., & Herdman, M. (2015). Assessing the health of the general population in England: How do the three- and five-level versions of EQ-5D compare? Health and Quality of Life Outcomes, 13, 171.CrossRefPubMedPubMedCentral
21.
go back to reference Ferreira, L. N., Ferreira, P. L., Ribeiro, F. P., & Pereira, L. N. (2016). Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults. Health and Quality of Life Outcomes, 14, 89.CrossRefPubMedPubMedCentral Ferreira, L. N., Ferreira, P. L., Ribeiro, F. P., & Pereira, L. N. (2016). Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults. Health and Quality of Life Outcomes, 14, 89.CrossRefPubMedPubMedCentral
22.
go back to reference Golicki, D., Niewada, M., Karlinska, A., Buczek, J., Kobayashi, A., Janssen, M. F., et al. (2015). Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Quality of Life Research, 24(6), 1555–1563.CrossRefPubMed Golicki, D., Niewada, M., Karlinska, A., Buczek, J., Kobayashi, A., Janssen, M. F., et al. (2015). Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Quality of Life Research, 24(6), 1555–1563.CrossRefPubMed
23.
go back to reference Greene, M. E., Rader, K. A., Garellick, G., Malchau, H., Freiberg, A. A., & Rolfson, O. (2015). The EQ-5D-5L improves on the EQ-5D-3L for health-related quality-of-life assessment in patients undergoing total hip arthroplasty. Clinical Orthopaedics and Related Research, 473(11), 3383–3390.CrossRefPubMed Greene, M. E., Rader, K. A., Garellick, G., Malchau, H., Freiberg, A. A., & Rolfson, O. (2015). The EQ-5D-5L improves on the EQ-5D-3L for health-related quality-of-life assessment in patients undergoing total hip arthroplasty. Clinical Orthopaedics and Related Research, 473(11), 3383–3390.CrossRefPubMed
24.
go back to reference Jia, Y. X., Cui, F. Q., Li, L., Zhang, D. L., Zhang, G. M., Wang, F. Z., et al. (2014). Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Quality of Life Research, 23(8), 2355–2363.CrossRefPubMed Jia, Y. X., Cui, F. Q., Li, L., Zhang, D. L., Zhang, G. M., Wang, F. Z., et al. (2014). Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Quality of Life Research, 23(8), 2355–2363.CrossRefPubMed
25.
go back to reference Pan, C. W., Sun, H. P., Wang, X., Ma, Q., Xu, Y., Luo, N., et al. (2015). The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Quality of Life Research, 24(7), 1767–1774.CrossRefPubMed Pan, C. W., Sun, H. P., Wang, X., Ma, Q., Xu, Y., Luo, N., et al. (2015). The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Quality of Life Research, 24(7), 1767–1774.CrossRefPubMed
26.
go back to reference Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care, 45(3), 259–263.CrossRefPubMed Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care, 45(3), 259–263.CrossRefPubMed
27.
go back to reference Yfantopoulos, J. N., & Chantzaras, A. E. (2016). Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece. The European Journal of Health Economics, 18, 519–531.CrossRefPubMed Yfantopoulos, J. N., & Chantzaras, A. E. (2016). Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece. The European Journal of Health Economics, 18, 519–531.CrossRefPubMed
28.
go back to reference Yfantopoulos, J., Chantzaras, A., & Kontodimas, S. (2017). Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. Archives of Dermatological Research, 309(5), 357–370.CrossRefPubMed Yfantopoulos, J., Chantzaras, A., & Kontodimas, S. (2017). Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. Archives of Dermatological Research, 309(5), 357–370.CrossRefPubMed
29.
go back to reference Conner-Spady, B. L., Marshall, D. A., Bohm, E., Dunbar, M. J., Loucks, L., Al Khudairy, A., et al. (2015). Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement. Quality of Life Research, 24(7), 1775–1784.CrossRefPubMed Conner-Spady, B. L., Marshall, D. A., Bohm, E., Dunbar, M. J., Loucks, L., Al Khudairy, A., et al. (2015). Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement. Quality of Life Research, 24(7), 1775–1784.CrossRefPubMed
30.
go back to reference Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value Health, 11(2), 275–284.CrossRefPubMed Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value Health, 11(2), 275–284.CrossRefPubMed
31.
go back to reference Kim, S. H., Kim, H. J., Lee, S. I., & Jo, M. W. (2012). Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Quality of Life Research, 21(6), 1065–1073.CrossRefPubMed Kim, S. H., Kim, H. J., Lee, S. I., & Jo, M. W. (2012). Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Quality of Life Research, 21(6), 1065–1073.CrossRefPubMed
32.
go back to reference Pattanaphesaj, J., & Thavorncharoensap, M. (2015). Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health and Quality of Life Outcomes, 13, 14.CrossRefPubMedPubMedCentral Pattanaphesaj, J., & Thavorncharoensap, M. (2015). Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health and Quality of Life Outcomes, 13, 14.CrossRefPubMedPubMedCentral
33.
go back to reference Pickard, A. S., Wilke, C. T., Lin, H. W., & Lloyd, A. (2007). Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics, 25(5), 365–384.CrossRefPubMed Pickard, A. S., Wilke, C. T., Lin, H. W., & Lloyd, A. (2007). Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics, 25(5), 365–384.CrossRefPubMed
34.
go back to reference Sakthong, P., Sonsa-Ardjit, N., Sukarnjanaset, P., & Munpan, W. (2015). Psychometric properties of the EQ-5D-5L in Thai patients with chronic diseases. Quality of Life Research, 24(12), 3015–3022.CrossRefPubMed Sakthong, P., Sonsa-Ardjit, N., Sukarnjanaset, P., & Munpan, W. (2015). Psychometric properties of the EQ-5D-5L in Thai patients with chronic diseases. Quality of Life Research, 24(12), 3015–3022.CrossRefPubMed
35.
go back to reference Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., et al. (2013). Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Quality of Life Research, 22(7), 1707–1716.CrossRefPubMed Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., et al. (2013). Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Quality of Life Research, 22(7), 1707–1716.CrossRefPubMed
36.
go back to reference Ali, F. M., Cueva, A. C., Vyas, J., Atwan, A. A., Salek, M. S., Finlay, A. Y., et al. (2017). A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. British Journal of Dermatology, 176(3), 577–593.CrossRefPubMed Ali, F. M., Cueva, A. C., Vyas, J., Atwan, A. A., Salek, M. S., Finlay, A. Y., et al. (2017). A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. British Journal of Dermatology, 176(3), 577–593.CrossRefPubMed
38.
go back to reference Ritchlin, C. T., & Krueger, J. G. (2016). New therapies for psoriasis and psoriatic arthritis. Current Opinion in Rheumatology, 28(3), 204–210.CrossRefPubMed Ritchlin, C. T., & Krueger, J. G. (2016). New therapies for psoriasis and psoriatic arthritis. Current Opinion in Rheumatology, 28(3), 204–210.CrossRefPubMed
39.
go back to reference Yang, Y., Brazier, J., & Longworth, L. (2015). EQ-5D in skin conditions: an assessment of validity and responsiveness. The European Journal of Health Economics, 16(9), 927–939.CrossRefPubMed Yang, Y., Brazier, J., & Longworth, L. (2015). EQ-5D in skin conditions: an assessment of validity and responsiveness. The European Journal of Health Economics, 16(9), 927–939.CrossRefPubMed
40.
go back to reference Fredriksson, T., & Pettersson, U. (1978). Severe psoriasis–oral therapy with a new retinoid. Dermatologica, 157(4), 238–244.CrossRefPubMed Fredriksson, T., & Pettersson, U. (1978). Severe psoriasis–oral therapy with a new retinoid. Dermatologica, 157(4), 238–244.CrossRefPubMed
41.
go back to reference van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health, 15(5), 708–715.CrossRefPubMed van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health, 15(5), 708–715.CrossRefPubMed
42.
go back to reference Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed
44.
go back to reference Rencz, F., Gulacsi, L., Drummond, M., Golicki, D., Prevolnik Rupel, V., Simon, J., et al. (2016). EQ-5D in central and eastern europe: 2000–2015. Quality of Life Research, 25(11), 2693–2710.CrossRefPubMed Rencz, F., Gulacsi, L., Drummond, M., Golicki, D., Prevolnik Rupel, V., Simon, J., et al. (2016). EQ-5D in central and eastern europe: 2000–2015. Quality of Life Research, 25(11), 2693–2710.CrossRefPubMed
45.
go back to reference Finlay, A. Y., & Khan, G. K. (1994). Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.CrossRefPubMed Finlay, A. Y., & Khan, G. K. (1994). Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.CrossRefPubMed
46.
go back to reference Basra, M. K., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008). The dermatology life quality index 1994–2007: A comprehensive review of validation data and clinical results. British Journal of Dermatology, 159(5), 997–1035.PubMed Basra, M. K., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008). The dermatology life quality index 1994–2007: A comprehensive review of validation data and clinical results. British Journal of Dermatology, 159(5), 997–1035.PubMed
47.
go back to reference Lewis, V., & Finlay, A. Y. (2004). 10 years experience of the Dermatology Life Quality Index (DLQI). Journal of Investigative Dermatology Symposium Proceedings, 9(2), 169–180.CrossRef Lewis, V., & Finlay, A. Y. (2004). 10 years experience of the Dermatology Life Quality Index (DLQI). Journal of Investigative Dermatology Symposium Proceedings, 9(2), 169–180.CrossRef
48.
go back to reference Hagg, D., Sundstrom, A., Eriksson, M., & Schmitt-Egenolf, M. (2015). Decision for biological treatment in real life is more strongly associated with the psoriasis area and severity index (PASI) than with the dermatology life quality index (DLQI). Journal of the European Academy of Dermatology and Venereology, 29(3), 452–456.CrossRefPubMed Hagg, D., Sundstrom, A., Eriksson, M., & Schmitt-Egenolf, M. (2015). Decision for biological treatment in real life is more strongly associated with the psoriasis area and severity index (PASI) than with the dermatology life quality index (DLQI). Journal of the European Academy of Dermatology and Venereology, 29(3), 452–456.CrossRefPubMed
49.
go back to reference Pathirana, D., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., Nast, A., et al. (2009). European S3-guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 23(Suppl 2), 1–70.CrossRefPubMed Pathirana, D., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., Nast, A., et al. (2009). European S3-guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 23(Suppl 2), 1–70.CrossRefPubMed
50.
go back to reference Wakkee, M., Thio, H. B., Spuls, P. I., de Jong, E. M., & Nijsten, T. (2008). Evaluation of the reimbursement criteria for biological therapies for psoriasis in the Netherlands. British Journal of Dermatology, 158(5), 1159–1161.CrossRefPubMed Wakkee, M., Thio, H. B., Spuls, P. I., de Jong, E. M., & Nijsten, T. (2008). Evaluation of the reimbursement criteria for biological therapies for psoriasis in the Netherlands. British Journal of Dermatology, 158(5), 1159–1161.CrossRefPubMed
51.
go back to reference Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E. M., Nast, A., et al. (2011). Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research, 303(1), 1–10.CrossRefPubMed Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E. M., Nast, A., et al. (2011). Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research, 303(1), 1–10.CrossRefPubMed
52.
go back to reference Rencz, F., Baji, P., Gulacsi, L., Karpati, S., Pentek, M., Poor, A. K., et al. (2016). Discrepancies between the dermatology life quality index and utility scores. Quality of Life Research, 25(7), 1687–1696.CrossRefPubMed Rencz, F., Baji, P., Gulacsi, L., Karpati, S., Pentek, M., Poor, A. K., et al. (2016). Discrepancies between the dermatology life quality index and utility scores. Quality of Life Research, 25(7), 1687–1696.CrossRefPubMed
53.
go back to reference Rencz, F., Kemeny, L., Gajdacsi, J. Z., Owczarek, W., Arenberger, P., Tiplica, G. S., et al. (2015). Use of biologics for psoriasis in Central and Eastern European countries. Journal of the European Academy of Dermatology and Venereology, 29(11), 2222–2230.CrossRefPubMed Rencz, F., Kemeny, L., Gajdacsi, J. Z., Owczarek, W., Arenberger, P., Tiplica, G. S., et al. (2015). Use of biologics for psoriasis in Central and Eastern European countries. Journal of the European Academy of Dermatology and Venereology, 29(11), 2222–2230.CrossRefPubMed
54.
go back to reference Gottlieb, A. B., & Armstrong, A. W. (2013). Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting. Journal of Rheumatology, 40(8), 1428–1433.CrossRefPubMed Gottlieb, A. B., & Armstrong, A. W. (2013). Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting. Journal of Rheumatology, 40(8), 1428–1433.CrossRefPubMed
55.
go back to reference Mease, P. J. (2011). Measures of psoriatic arthritis: Tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander/Newcastle enthesitis index (MEI), leeds enthesitis index (LEI), spondyloarthritis research consortium of Canada (SPARCC), Maastricht ankylosing spondylitis enthesis score (MASES), Leeds dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI). Arthritis Care Research, 63(Suppl 11), S64–S85.CrossRefPubMed Mease, P. J. (2011). Measures of psoriatic arthritis: Tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander/Newcastle enthesitis index (MEI), leeds enthesitis index (LEI), spondyloarthritis research consortium of Canada (SPARCC), Maastricht ankylosing spondylitis enthesis score (MASES), Leeds dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI). Arthritis Care Research, 63(Suppl 11), S64–S85.CrossRefPubMed
56.
go back to reference Janssen, M. F., Birnie, E., & Bonsel, G. J. (2007). Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon’s indices. Quality of Life Research, 16(5), 895–904.CrossRefPubMedCentral Janssen, M. F., Birnie, E., & Bonsel, G. J. (2007). Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon’s indices. Quality of Life Research, 16(5), 895–904.CrossRefPubMedCentral
57.
go back to reference Shannon, C. E. (1948). The mathematical theory of communication. The Bell System Technical Journal, 27, 379–423.CrossRef Shannon, C. E. (1948). The mathematical theory of communication. The Bell System Technical Journal, 27, 379–423.CrossRef
58.
go back to reference Shannon, C. E., & Weaver, W. (1949). The Mathematical Theory of Communication (pp. 104–107). Urbana: University of Illinois Press. Shannon, C. E., & Weaver, W. (1949). The Mathematical Theory of Communication (pp. 104–107). Urbana: University of Illinois Press.
59.
go back to reference Swinscow, T., & Campbell, M. (2002). Statistics at square one. London, United Kingdom: BMJ. Swinscow, T., & Campbell, M. (2002). Statistics at square one. London, United Kingdom: BMJ.
60.
go back to reference Heredi, E., Rencz, F., Balogh, O., Gulacsi, L., Herszenyi, K., Hollo, P., et al. (2014). Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: A cross-sectional study in psoriasis from Hungary. The European Journal of Health Economics, 15(Suppl 1), S111–S119.CrossRefPubMed Heredi, E., Rencz, F., Balogh, O., Gulacsi, L., Herszenyi, K., Hollo, P., et al. (2014). Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: A cross-sectional study in psoriasis from Hungary. The European Journal of Health Economics, 15(Suppl 1), S111–S119.CrossRefPubMed
61.
go back to reference Moradi, M., Rencz, F., Brodszky, V., Moradi, A., Balogh, O., & Gulacsi, L. (2015). Health status and quality of life in patients with psoriasis: An Iranian cross-sectional survey. Archives of Iranian Medicine, 18(3), 153–159.PubMed Moradi, M., Rencz, F., Brodszky, V., Moradi, A., Balogh, O., & Gulacsi, L. (2015). Health status and quality of life in patients with psoriasis: An Iranian cross-sectional survey. Archives of Iranian Medicine, 18(3), 153–159.PubMed
62.
go back to reference Rencz, F., Brodszky, V., Péntek, M., Balogh, O., Remenyik, É., Szegedi, A., et al. (2014). Disease burden of psoriasis associated with psoriatic arthritis in Hungary. Orvosi Hetilap, 155(48), 1913–1921.CrossRefPubMed Rencz, F., Brodszky, V., Péntek, M., Balogh, O., Remenyik, É., Szegedi, A., et al. (2014). Disease burden of psoriasis associated with psoriatic arthritis in Hungary. Orvosi Hetilap, 155(48), 1913–1921.CrossRefPubMed
63.
go back to reference Rencz, F., Hollo, P., Karpati, S., Pentek, M., Remenyik, E., Szegedi, A., et al. (2015). Moderate to severe psoriasis patients’ subjective future expectations regarding health-related quality of life and longevity. Journal of the European Academy of Dermatology and Venereology, 29(7), 1398–1405.CrossRefPubMed Rencz, F., Hollo, P., Karpati, S., Pentek, M., Remenyik, E., Szegedi, A., et al. (2015). Moderate to severe psoriasis patients’ subjective future expectations regarding health-related quality of life and longevity. Journal of the European Academy of Dermatology and Venereology, 29(7), 1398–1405.CrossRefPubMed
65.
go back to reference Versteegh, M. M., Vermeulen, K. M., Evers, S. M. A. A., de Wit, G. A., Prenger, R., & Stolk, E. A. (2016). Dutch tariff for the five-level version of EQ-5D. Value Health, 19(4), 343–352.CrossRef Versteegh, M. M., Vermeulen, K. M., Evers, S. M. A. A., de Wit, G. A., Prenger, R., & Stolk, E. A. (2016). Dutch tariff for the five-level version of EQ-5D. Value Health, 19(4), 343–352.CrossRef
66.
go back to reference Puzenat, E., Bronsard, V., Prey, S., Gourraud, P. A., Aractingi, S., Bagot, M., et al. (2010). What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. Journal of the European Academy of Dermatology and Venereology, 24(Suppl 2), 10–16.CrossRefPubMed Puzenat, E., Bronsard, V., Prey, S., Gourraud, P. A., Aractingi, S., Bagot, M., et al. (2010). What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. Journal of the European Academy of Dermatology and Venereology, 24(Suppl 2), 10–16.CrossRefPubMed
67.
go back to reference Nast, A., & Schmitt, J. (2013). Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 68(6), 1040–1041.CrossRefPubMed Nast, A., & Schmitt, J. (2013). Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 68(6), 1040–1041.CrossRefPubMed
68.
go back to reference Blome, C., Beikert, F. C., Rustenbach, S. J., & Augustin, M. (2013). Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Archives of Dermatological Research, 305(3), 197–204.CrossRefPubMed Blome, C., Beikert, F. C., Rustenbach, S. J., & Augustin, M. (2013). Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Archives of Dermatological Research, 305(3), 197–204.CrossRefPubMed
69.
go back to reference Norlin, J. M., Steen Carlsson, K., Persson, U., & Schmitt-Egenolf, M. (2012). Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. British Journal of Dermatology, 166(4), 797–802.CrossRefPubMed Norlin, J. M., Steen Carlsson, K., Persson, U., & Schmitt-Egenolf, M. (2012). Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. British Journal of Dermatology, 166(4), 797–802.CrossRefPubMed
70.
go back to reference Szende, A., & Nemeth, R. (2003). Health-related quality of life of the Hungarian population. Orvosi Hetilap, 144(34), 1667–1674.PubMed Szende, A., & Nemeth, R. (2003). Health-related quality of life of the Hungarian population. Orvosi Hetilap, 144(34), 1667–1674.PubMed
71.
go back to reference Baji, P., Brodszky, V., Rencz, F., Boncz, I., Gulacsi, L., & Pentek, M. (2015). Health status of the Hungarian population between 2000-2010. Orvosi Hetilap, 156(50), 2035–2044.CrossRefPubMed Baji, P., Brodszky, V., Rencz, F., Boncz, I., Gulacsi, L., & Pentek, M. (2015). Health status of the Hungarian population between 2000-2010. Orvosi Hetilap, 156(50), 2035–2044.CrossRefPubMed
72.
go back to reference Gudjonsson, J. E., & Elder, J. T. (2007). Psoriasis: epidemiology. Clinics in Dermatology, 25(6), 535–546.CrossRefPubMed Gudjonsson, J. E., & Elder, J. T. (2007). Psoriasis: epidemiology. Clinics in Dermatology, 25(6), 535–546.CrossRefPubMed
74.
go back to reference Hagg, D., Eriksson, M., Sundstrom, A., & Schmitt-Egenolf, M. (2013). The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS ONE, 8(5), e63619.CrossRefPubMedPubMedCentral Hagg, D., Eriksson, M., Sundstrom, A., & Schmitt-Egenolf, M. (2013). The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS ONE, 8(5), e63619.CrossRefPubMedPubMedCentral
75.
go back to reference Kojanova, M., Fialova, J., Cetkovska, P., Gkalpakiotis, S., Jircikova, J., Dolezal, T., et al. (2017). Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. International Journal of Dermatology, 56(4), 428–434.CrossRefPubMed Kojanova, M., Fialova, J., Cetkovska, P., Gkalpakiotis, S., Jircikova, J., Dolezal, T., et al. (2017). Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. International Journal of Dermatology, 56(4), 428–434.CrossRefPubMed
76.
go back to reference Swinburn, P., Lloyd, A., Boye, K. S., Edson-Heredia, E., Bowman, L., & Janssen, B. (2013). Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health, 16(8), 1156–1162.CrossRefPubMed Swinburn, P., Lloyd, A., Boye, K. S., Edson-Heredia, E., Bowman, L., & Janssen, B. (2013). Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health, 16(8), 1156–1162.CrossRefPubMed
77.
go back to reference Pickard, A. S., Gooderham, M., Hartz, S., & Nicolay, C. (2017). EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. Journal of Medical Economics, 20(1), 19–27.CrossRefPubMed Pickard, A. S., Gooderham, M., Hartz, S., & Nicolay, C. (2017). EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. Journal of Medical Economics, 20(1), 19–27.CrossRefPubMed
78.
go back to reference Buchholz, I., Thielker, K., Feng, Y. S., Kupatz, P., & Kohlmann, T. (2015). Measuring changes in health over time using the EQ-5D 3L and 5L: a head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample. Quality of Life Research, 24(4), 829–835.CrossRefPubMed Buchholz, I., Thielker, K., Feng, Y. S., Kupatz, P., & Kohlmann, T. (2015). Measuring changes in health over time using the EQ-5D 3L and 5L: a head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample. Quality of Life Research, 24(4), 829–835.CrossRefPubMed
Metagegevens
Titel
Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients
Auteurs
Adrienn Katalin Poór
Fanni Rencz
Valentin Brodszky
László Gulácsi
Zsuzsanna Beretzky
Bernadett Hidvégi
Péter Holló
Sarolta Kárpáti
Márta Péntek
Publicatiedatum
05-09-2017
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 12/2017
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1699-x

Andere artikelen Uitgave 12/2017

Quality of Life Research 12/2017 Naar de uitgave